Predictive factors of impaired response to COH (≤ 9 MII oocytes) for fertility preservation before lymphoma treatment.
| Disease characteristic . | OR (95% CI) . | P-value . |
|---|---|---|
| Lymphoma | 0.2 | |
| Hodgkin | Reference | |
| Non-Hodgkin | 1.2 (0.9–1.7) | |
| Ann-Arbor stage | 0.9 | |
| I–II (localized) | Reference | |
| III–IV (disseminated) | 1.0 (0.7–1.4) | |
| Adverse clinical symptoms | 0.7 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| Adverse biological parameters | 0.1 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| ECOG-PS | 0.9 | |
| 0 | Reference | |
| ≥1 | 0.9 (0.7–1.4) |
| Disease characteristic . | OR (95% CI) . | P-value . |
|---|---|---|
| Lymphoma | 0.2 | |
| Hodgkin | Reference | |
| Non-Hodgkin | 1.2 (0.9–1.7) | |
| Ann-Arbor stage | 0.9 | |
| I–II (localized) | Reference | |
| III–IV (disseminated) | 1.0 (0.7–1.4) | |
| Adverse clinical symptoms | 0.7 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| Adverse biological parameters | 0.1 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| ECOG-PS | 0.9 | |
| 0 | Reference | |
| ≥1 | 0.9 (0.7–1.4) |
COH, ovarian stimulation; MII, metaphase II; OR, odds ratio; ECOG-PS, Eastern Cooperative Oncology Group Performance Status.
All results were adjusted for POSEIDON criteria before ovarian stimulation (Groups 3 and 4).
Predictive factors of impaired response to COH (≤ 9 MII oocytes) for fertility preservation before lymphoma treatment.
| Disease characteristic . | OR (95% CI) . | P-value . |
|---|---|---|
| Lymphoma | 0.2 | |
| Hodgkin | Reference | |
| Non-Hodgkin | 1.2 (0.9–1.7) | |
| Ann-Arbor stage | 0.9 | |
| I–II (localized) | Reference | |
| III–IV (disseminated) | 1.0 (0.7–1.4) | |
| Adverse clinical symptoms | 0.7 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| Adverse biological parameters | 0.1 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| ECOG-PS | 0.9 | |
| 0 | Reference | |
| ≥1 | 0.9 (0.7–1.4) |
| Disease characteristic . | OR (95% CI) . | P-value . |
|---|---|---|
| Lymphoma | 0.2 | |
| Hodgkin | Reference | |
| Non-Hodgkin | 1.2 (0.9–1.7) | |
| Ann-Arbor stage | 0.9 | |
| I–II (localized) | Reference | |
| III–IV (disseminated) | 1.0 (0.7–1.4) | |
| Adverse clinical symptoms | 0.7 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| Adverse biological parameters | 0.1 | |
| Yes | 0.9 (0.7–1.3) | |
| No | Reference | |
| ECOG-PS | 0.9 | |
| 0 | Reference | |
| ≥1 | 0.9 (0.7–1.4) |
COH, ovarian stimulation; MII, metaphase II; OR, odds ratio; ECOG-PS, Eastern Cooperative Oncology Group Performance Status.
All results were adjusted for POSEIDON criteria before ovarian stimulation (Groups 3 and 4).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
